Literature DB >> 23219818

PML tumor suppressor protein is required for HCV production.

Misao Kuroki1, Yasuo Ariumi, Makoto Hijikata, Masanori Ikeda, Hiromichi Dansako, Takaji Wakita, Kunitada Shimotohno, Nobuyuki Kato.   

Abstract

PML tumor suppressor protein, which forms discrete nuclear structures termed PML-nuclear bodies, has been associated with several cellular functions, including cell proliferation, apoptosis and antiviral defense. Recently, it was reported that the HCV core protein colocalizes with PML in PML-NBs and abrogates the PML function through interaction with PML. However, role(s) of PML in HCV life cycle is unknown. To test whether or not PML affects HCV life cycle, we examined the level of secreted HCV core and the infectivity of HCV in the culture supernatants as well as the level of HCV RNA in HuH-7-derived RSc cells, in which HCV-JFH1 can infect and efficiently replicate, stably expressing short hairpin RNA targeted to PML. In this context, the level of secreted HCV core and the infectivity in the supernatants from PML knockdown cells was remarkably reduced, whereas the level of HCV RNA in the PML knockdown cells was not significantly affected in spite of very effective knockdown of PML. In fact, we showed that PML is unrelated to HCV RNA replication using the subgenomic HCV-JFH1 replicon RNA, JRN/3-5B. Furthermore, the infectivity of HCV-like particle in the culture supernatants was significantly reduced in PML knockdown JRN/3-5B cells expressing core to NS2 coding region of HCV-JFH1 genome using the trans-packaging system. Finally, we also demonstrated that INI1 and DDX5, the PML-related proteins, are involved in HCV production. Taken together, these findings suggest that PML is required for HCV production. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219818     DOI: 10.1016/j.bbrc.2012.11.108

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases.

Authors:  Megha Haridas Upadya; Jude Juventus Aweya; Yee-Joo Tan
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 2.  Emerging Role of PML Nuclear Bodies in Innate Immune Signaling.

Authors:  Myriam Scherer; Thomas Stamminger
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 3.  Multiple functions of DDX3 RNA helicase in gene regulation, tumorigenesis, and viral infection.

Authors:  Yasuo Ariumi
Journal:  Front Genet       Date:  2014-12-05       Impact factor: 4.599

Review 4.  DDX5: an expectable treater for viral infection- a literature review.

Authors:  Minghui Hu; Hongying Zheng; Jingqi Wu; Yue Sun; Tianying Wang; Shuang Chen
Journal:  Ann Transl Med       Date:  2022-06

5.  The interferon-induced antiviral protein PML (TRIM19) promotes the restriction and transcriptional silencing of lentiviruses in a context-specific, isoform-specific fashion.

Authors:  Nasser Masroori; Natacha Merindol; Lionel Berthoux
Journal:  Retrovirology       Date:  2016-03-22       Impact factor: 4.602

Review 6.  DDX5 RNA Helicases: Emerging Roles in Viral Infection.

Authors:  Wenyu Cheng; Guohua Chen; Huaijie Jia; Xiaobing He; Zhizhong Jing
Journal:  Int J Mol Sci       Date:  2018-04-09       Impact factor: 5.923

7.  Distinct DDX DEAD-box RNA helicases cooperate to modulate the HIV-1 Rev function.

Authors:  Mariko Yasuda-Inoue; Misao Kuroki; Yasuo Ariumi
Journal:  Biochem Biophys Res Commun       Date:  2013-04-19       Impact factor: 3.575

Review 8.  SUMOylation in Viral Replication and Antiviral Defense.

Authors:  Yao Fan; Xiang Li; Lei Zhang; Zhi Zong; Fangwei Wang; Jun Huang; Linghui Zeng; Chong Zhang; Haiyan Yan; Long Zhang; Fangfang Zhou
Journal:  Adv Sci (Weinh)       Date:  2022-01-21       Impact factor: 16.806

9.  Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection.

Authors:  Yasuo Ariumi
Journal:  J Virol       Date:  2022-02-02       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.